产品
编 号：F748142
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1969309-56-5
产品详情
生物活性：
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
体内研究：
Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退。Animal Model:6 to 12-week-old female NSG? (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors.
Dosage:2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:i.p.; once weekly; for 28 days
Result:Blocked growth of lung and ovarian cancer PDX models.
体外研究：
Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长。Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物。
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
体内研究：
Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退。Animal Model:6 to 12-week-old female NSG? (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors.
Dosage:2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:i.p.; once weekly; for 28 days
Result:Blocked growth of lung and ovarian cancer PDX models.
体外研究：
Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长。Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备